Photodynamic therapy involves an antiangiogenic mechanism and is enhanced by ferrochelatase inhibitor in urothelial carcinoma

Keiji Inoue, Hideo Fukuhara, Atsushi Kurabayashi, Mutsuo Furihata, Masayuki Tsuda, Keisuke Nagakawa, Hirofumi Fujita, Kozo Utsumi, Taro Shuin

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The purpose of the present study was to investigate the mechanism of photodynamic therapy (PDT) supplemented with exogenously added 5-aminolevulinic acid (ALA) on human urothelial cancer (UC). Moreover, we aimed to determine whether the therapeutic effects of ALA-based PDT (ALA-PDT) for UC could be enhanced by deferoxamine (DFX), an inhibitor of ferrochelatase. The efficiency of ALA-PDT on these cells was analyzed using flow cytometry and the type of cell death was also assessed. The ALA-PDT promoting effect of DFX was examined on both UC cells and human umbilical vein endothelial cells (HUVEC). The ALA-PDT decreased levels of mitochondrial membrane potential and induced cell death mainly via apoptosis in these cells. Moreover, inhibition of ferrochelatase by DFX led to an increase of protoporphyrin IX (PpIX) accumulation and enhanced the effect of ALA-PDT on UC cells. We further investigated the effect of DFX on in vivo PDT with a tumor-bearing animal model and found that DFX efficiently enhanced tumor cell apoptosis. ALA-PDT induced death of neovascular endothelial cells in tumors but did not affect small vessel endothelial cells in normal tissues surrounding the tumor. Furthermore, DFX enhanced inhibition of neovascularization. These results demonstrated ALA-PDT dominantly induced apoptosis over necrosis by direct action on UC as well as via antiangiogenic action on neovacular endothelial cells, suggesting that the therapeutic damage by ALA-PDT could be kept to a minimum in the surrounding normal tissues. In addition, increased accumulation of PpIX by DFX could enhance this effectiveness of ALA-PDT.

Original languageEnglish
Pages (from-to)765-772
Number of pages8
JournalCancer Science
Volume104
Issue number6
DOIs
Publication statusPublished - Jun 2013

Fingerprint

Ferrochelatase
Aminolevulinic Acid
Photochemotherapy
Deferoxamine
Carcinoma
Neoplasms
Endothelial Cells
Apoptosis
Cell Death
Mitochondrial Membrane Potential
Human Umbilical Vein Endothelial Cells
Therapeutic Uses

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Inoue, K., Fukuhara, H., Kurabayashi, A., Furihata, M., Tsuda, M., Nagakawa, K., ... Shuin, T. (2013). Photodynamic therapy involves an antiangiogenic mechanism and is enhanced by ferrochelatase inhibitor in urothelial carcinoma. Cancer Science, 104(6), 765-772. https://doi.org/10.1111/cas.12147

Photodynamic therapy involves an antiangiogenic mechanism and is enhanced by ferrochelatase inhibitor in urothelial carcinoma. / Inoue, Keiji; Fukuhara, Hideo; Kurabayashi, Atsushi; Furihata, Mutsuo; Tsuda, Masayuki; Nagakawa, Keisuke; Fujita, Hirofumi; Utsumi, Kozo; Shuin, Taro.

In: Cancer Science, Vol. 104, No. 6, 06.2013, p. 765-772.

Research output: Contribution to journalArticle

Inoue, K, Fukuhara, H, Kurabayashi, A, Furihata, M, Tsuda, M, Nagakawa, K, Fujita, H, Utsumi, K & Shuin, T 2013, 'Photodynamic therapy involves an antiangiogenic mechanism and is enhanced by ferrochelatase inhibitor in urothelial carcinoma', Cancer Science, vol. 104, no. 6, pp. 765-772. https://doi.org/10.1111/cas.12147
Inoue, Keiji ; Fukuhara, Hideo ; Kurabayashi, Atsushi ; Furihata, Mutsuo ; Tsuda, Masayuki ; Nagakawa, Keisuke ; Fujita, Hirofumi ; Utsumi, Kozo ; Shuin, Taro. / Photodynamic therapy involves an antiangiogenic mechanism and is enhanced by ferrochelatase inhibitor in urothelial carcinoma. In: Cancer Science. 2013 ; Vol. 104, No. 6. pp. 765-772.
@article{c2980c1f715342ed809ae7f067b9b857,
title = "Photodynamic therapy involves an antiangiogenic mechanism and is enhanced by ferrochelatase inhibitor in urothelial carcinoma",
abstract = "The purpose of the present study was to investigate the mechanism of photodynamic therapy (PDT) supplemented with exogenously added 5-aminolevulinic acid (ALA) on human urothelial cancer (UC). Moreover, we aimed to determine whether the therapeutic effects of ALA-based PDT (ALA-PDT) for UC could be enhanced by deferoxamine (DFX), an inhibitor of ferrochelatase. The efficiency of ALA-PDT on these cells was analyzed using flow cytometry and the type of cell death was also assessed. The ALA-PDT promoting effect of DFX was examined on both UC cells and human umbilical vein endothelial cells (HUVEC). The ALA-PDT decreased levels of mitochondrial membrane potential and induced cell death mainly via apoptosis in these cells. Moreover, inhibition of ferrochelatase by DFX led to an increase of protoporphyrin IX (PpIX) accumulation and enhanced the effect of ALA-PDT on UC cells. We further investigated the effect of DFX on in vivo PDT with a tumor-bearing animal model and found that DFX efficiently enhanced tumor cell apoptosis. ALA-PDT induced death of neovascular endothelial cells in tumors but did not affect small vessel endothelial cells in normal tissues surrounding the tumor. Furthermore, DFX enhanced inhibition of neovascularization. These results demonstrated ALA-PDT dominantly induced apoptosis over necrosis by direct action on UC as well as via antiangiogenic action on neovacular endothelial cells, suggesting that the therapeutic damage by ALA-PDT could be kept to a minimum in the surrounding normal tissues. In addition, increased accumulation of PpIX by DFX could enhance this effectiveness of ALA-PDT.",
author = "Keiji Inoue and Hideo Fukuhara and Atsushi Kurabayashi and Mutsuo Furihata and Masayuki Tsuda and Keisuke Nagakawa and Hirofumi Fujita and Kozo Utsumi and Taro Shuin",
year = "2013",
month = "6",
doi = "10.1111/cas.12147",
language = "English",
volume = "104",
pages = "765--772",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Photodynamic therapy involves an antiangiogenic mechanism and is enhanced by ferrochelatase inhibitor in urothelial carcinoma

AU - Inoue, Keiji

AU - Fukuhara, Hideo

AU - Kurabayashi, Atsushi

AU - Furihata, Mutsuo

AU - Tsuda, Masayuki

AU - Nagakawa, Keisuke

AU - Fujita, Hirofumi

AU - Utsumi, Kozo

AU - Shuin, Taro

PY - 2013/6

Y1 - 2013/6

N2 - The purpose of the present study was to investigate the mechanism of photodynamic therapy (PDT) supplemented with exogenously added 5-aminolevulinic acid (ALA) on human urothelial cancer (UC). Moreover, we aimed to determine whether the therapeutic effects of ALA-based PDT (ALA-PDT) for UC could be enhanced by deferoxamine (DFX), an inhibitor of ferrochelatase. The efficiency of ALA-PDT on these cells was analyzed using flow cytometry and the type of cell death was also assessed. The ALA-PDT promoting effect of DFX was examined on both UC cells and human umbilical vein endothelial cells (HUVEC). The ALA-PDT decreased levels of mitochondrial membrane potential and induced cell death mainly via apoptosis in these cells. Moreover, inhibition of ferrochelatase by DFX led to an increase of protoporphyrin IX (PpIX) accumulation and enhanced the effect of ALA-PDT on UC cells. We further investigated the effect of DFX on in vivo PDT with a tumor-bearing animal model and found that DFX efficiently enhanced tumor cell apoptosis. ALA-PDT induced death of neovascular endothelial cells in tumors but did not affect small vessel endothelial cells in normal tissues surrounding the tumor. Furthermore, DFX enhanced inhibition of neovascularization. These results demonstrated ALA-PDT dominantly induced apoptosis over necrosis by direct action on UC as well as via antiangiogenic action on neovacular endothelial cells, suggesting that the therapeutic damage by ALA-PDT could be kept to a minimum in the surrounding normal tissues. In addition, increased accumulation of PpIX by DFX could enhance this effectiveness of ALA-PDT.

AB - The purpose of the present study was to investigate the mechanism of photodynamic therapy (PDT) supplemented with exogenously added 5-aminolevulinic acid (ALA) on human urothelial cancer (UC). Moreover, we aimed to determine whether the therapeutic effects of ALA-based PDT (ALA-PDT) for UC could be enhanced by deferoxamine (DFX), an inhibitor of ferrochelatase. The efficiency of ALA-PDT on these cells was analyzed using flow cytometry and the type of cell death was also assessed. The ALA-PDT promoting effect of DFX was examined on both UC cells and human umbilical vein endothelial cells (HUVEC). The ALA-PDT decreased levels of mitochondrial membrane potential and induced cell death mainly via apoptosis in these cells. Moreover, inhibition of ferrochelatase by DFX led to an increase of protoporphyrin IX (PpIX) accumulation and enhanced the effect of ALA-PDT on UC cells. We further investigated the effect of DFX on in vivo PDT with a tumor-bearing animal model and found that DFX efficiently enhanced tumor cell apoptosis. ALA-PDT induced death of neovascular endothelial cells in tumors but did not affect small vessel endothelial cells in normal tissues surrounding the tumor. Furthermore, DFX enhanced inhibition of neovascularization. These results demonstrated ALA-PDT dominantly induced apoptosis over necrosis by direct action on UC as well as via antiangiogenic action on neovacular endothelial cells, suggesting that the therapeutic damage by ALA-PDT could be kept to a minimum in the surrounding normal tissues. In addition, increased accumulation of PpIX by DFX could enhance this effectiveness of ALA-PDT.

UR - http://www.scopus.com/inward/record.url?scp=84878166976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878166976&partnerID=8YFLogxK

U2 - 10.1111/cas.12147

DO - 10.1111/cas.12147

M3 - Article

C2 - 23480042

AN - SCOPUS:84878166976

VL - 104

SP - 765

EP - 772

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 6

ER -